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Background: This study compared the glycemic effectiveness of three metformin-based dual therapies according to baseline 
hemoglobin A1c (HbA1c) to evaluate the appropriateness of the guideline enforced by the National Health Insurance Corpora-
tion of Korea for initial medication of type 2 diabetes (T2D).
Methods: This prospective observational study was conducted across 24 weeks for drug-naïve Korean T2D patients with HbA1c 
greater than 7.5%. Subjects were first divided into three groups based on the agent combined with metformin (group 1, gliclazide-
modified release or glimepiride; group 2, pioglitazone; group 3, sitagliptin). Subjects were also classified into three categories ac-
cording to baseline HbA1c (category I, 7.5%≤HbA1c<9.0%; category II, 9.0%≤HbA1c<11.0%; category III, 11.0%≤HbA1c). 
Results: Among 116 subjects, 99 subjects completed the study, with 88 subjects maintaining the initial medication. While each 
of the metformin-based dual therapies showed a significant decrease in HbA1c (group 1, 8.9% to 6.4%; group 2, 9.0% to 6.6%; 
group 3, 9.3% to 6.3%; P<0.001 for each), there was no significant difference in the magnitude of HbA1c change among the 
groups. While the three HbA1c categories showed significantly different baseline HbA1c levels (8.2% vs. 9.9% vs. 11.9%; P<0.001), 
endpoint HbA1c was not different (6.4% vs. 6.6% vs. 6.0%; P=0.051).
Conclusion: The three dual therapies using a combination of metformin and either sulfonylurea, pioglitazone, or sitagliptin 
showed similar glycemic effectiveness among drug-naïve Korean T2D patients. In addition, these regimens were similarly effec-
tive across a wide range of baseline HbA1c levels.
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INTRODUCTION
In reducing microvascular and macrovascular diabetic com-
plications, there has been little controversy on the need for ear-
ly intensive glycemic control in subjects with newly detected 
type 2 diabetes (T2D) since the late 1990s [1]. This consensus 
is essentially based on the results of controlled clinical trials, 
such as the Kumamoto study and UK Prospective Diabetes 
Study, which are prospective randomized studies including a 
large number of Asian and Western subjects, respectively [1-3]. 
However, optimal or recommended regimens regarding the se-
lection of hypoglycemic agents to effectively and safely achieve 
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good glycemic status have differed slightly between several 
guidelines [4-6]. In 2011, the Korean Diabetes Association 
recommended Clinical Practice Guidelines for T2D in Korea 
[5]. This guideline recommended lifestyle interventions with 
metformin as an initial treatment regimen. In addition, initial 
treatment with a combination of oral hypoglycemic agents 
(OHAs) or insulin was also recommended at a hemoglobin 
A1c (HbA1c) level greater than 8.0% at the time of T2D diag-
nosis. In the same year, the National Health Insurance Corpo-
ration (NHIC) established guidelines to enforce metformin-
preferred monotherapy as a general initial treatment regimen 
and metformin-based dual therapies with sulphonylurea (SU), 
pioglitazone, or DPP4-inhibitor as an initial regimen at an 
HbA1c level greater than 7.5%. Recently, Yoon et al. [7] re-
ported a reduction in HbA1c level after conducting a double-
blind, randomized controlled study over a 48-week period on 
the efficacy of glimepiride, metformin, and rosiglitazone as 
antidiabetic monotherapies in drug-naïve, Korean T2D pa-
tients. The study showed no statistical difference in the efficacy 
of glimepiride, metformin, and rosiglitazone as antidiabetic 
monotherapy. However, there has been no report on the effi-
cacy or safety of metformin-based dual combination therapy 
for drug-naïve or newly detected Korean T2D patients.
 This study was designed to evaluate the effectiveness of gly-
cemic control in drug-naïve or newly detected Korean T2D 
patients receiving metformin-based dual combination therapy 
with SU, pioglitazone, or DPP4-inhibitor.
METHODS
Study design
This prospective, nonrandomized, open-label study was con-
ducted at a single center by closely observing metabolic pa-
rameters for up to 24 weeks between November 2011 and 
March 2013. The study protocol entitled ‘Efficacy of antidia-
betic medications recommended by government guidelines 
for newly diagnosed or currently medicated T2D patients on 
metformin and sulfonylurea’ was reviewed by the local ethics 
committee (2011-0670-001). To adhere to the guidelines of 
NHIC and Institutional Review Board for reimbursement, all 
subjects with an initial HbA1c level ≥7.5% received metformin 
and were recommended lifestyle modification; however, the 
selection of another OHA from SU, pioglitazone, or DPP4-in-
hibitor was at the discretion of the subjects’ physicians. In ad-
dition, physicians also determined all subsequent treatment 
decisions according to usual practice. Participants were exam-
ined every 12 to 13 weeks for 24 weeks after the initiation of 
metformin-based dual combination therapy with OHAs.
 We included only drug-naïve T2D patients with an initial 
HbA1c level ≥7.5% who were first-time visitors to the Sever-
ance Diabetes Center. In the final analysis, subjects were ex-
cluded if they had a recent (≤6 months) history of major car-
diovascular event, including myocardial infarction, unstable 
angina, moderate to severe congestive heart failure, and/or 
stroke. In addition, patients with a current hepatic (aspartate 
aminotransferase [AST], and alanine aminotransferase [ALT] 
>2.5-fold the upper normal limit), renal (serum creatinine 
>1.5 mg/dL in men, >1.4 mg/dL in women), hematologic, or 
gastrointestinal disease or those that had undergone systemic 
corticosteroid treatment in the previous 12 weeks were exclud-
ed. Subjects recruited for the study were classified into three 
groups according to the combination of metformin and OHA: 
group I (metformin and either gliclazide-MR or glimepiride), 
group II (metformin and 15 mg pioglitazone), and group III 
(metformin and 100 mg sitagliptin).
 Complete available medical records from other departments 
or other institutions were reviewed, and laboratory results 
meeting the criteria for diabetes (fasting serum glucose ≥126 
mg/dL, postprandial serum glucose ≥200 mg/dL, or HbA1c 
≥6.5%) were regarded as the onset of diabetes. If data were 
unavailable, the onset and duration of diabetes were deter-
mined by subject recall. Subjects underwent a standardized 
mixed-meal stimulation test (Glucerna; Abbott Laboratories, 
Saint-Laurent, QC, Canada) (H4S 1Z; 2 cans, total 474 mL, 
474 kcal, 26 g fat, 45.8 g carbohydrate, and 19.8 g protein) for 
the evaluation of glucose metabolism. The glucose level after a 
mixed-meal stimulation test was regarded as the baseline post-
prandial glucose (PPG) level. Plasma glucose level was mea-
sured using the glucose oxidase method, and HbA1c was mea-
sured with high-performance liquid chromatography using 
Variant II Turbo (Bio-Rad Laboratories, Hercules, CA, USA). 
Plasma triglyceride, total cholesterol, high density lipoprotein 
cholesterol, blood urea nitrogen, creatinine, AST, and ALT lev-
els were assayed with a routine Hitachi 7600 autoanalyzer (Hit-
achi Instruments Service, Tokyo, Japan). Low density lipopro-
tein cholesterol level was calculated using Friedewald’s equa-
tion. Serum insulin and C-peptide levels were measured in du-
plicate using immunoradiometric assays (Beckman Coulter, 
Fullerton, CA, USA) with samples individually collected during 
the standardized mixed-meal stimulation test. Pancreatic β-cell 
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function and insulin sensitivity were determined by homeosta-
sis model assessment (HOMA) of pancreatic β-cell function 
(HOMA-β; [baseline insulin (μIU/mL)×20]/[0.055551×fast-
ing glucose (mg/dL)–3.5]) and HOMA of insulin resistance 
(HOMA-IR; [0.055551×fasting glucose (mg/L)×baseline insu-
lin (μIU/mL)]/22.5), respectively.
Tolerability and hypoglycemia assessment
Reasons for discontinuation of the study and treatment-in-
duced major hypoglycemia were recorded to assess tolerability 
and compliance. A major hypoglycemic event was defined as 
blood glucose ≤60 mg/dL accompanied by neurological symp-
toms consistent with hypoglycemia or an episode requiring 
intervention with intravenous glucose. In addition, other mi-
nor adverse events were obtained by patient self-report.
Effectiveness assessment
The primary endpoint was change in HbA1c and fasting and 
PPG levels from baseline to 24 weeks. The secondary endpoint 
was the frequency of successfully achieved target HbA1c 
(≤7.0%) level according to baseline HbA1c.
Statistics
Results are described as mean±standard deviation or median 
value (low quartile, high quartile). Analysis of variance test 
was used for comparison of baseline data among the three 
treatment groups. Kruskal-Wallis test was used for nonpara-
metric statistical analysis. Mann-Whitney test with Bonferroni 
correction was used as post hoc analysis for nonparametric 
statistical analysis. Wilcoxon signed rank test was used for 
comparison of pretreatment and posttreatment values. Multi-
ple linear regression test and Fisher exact test were performed 
for comparison of treatment effectiveness. Group I was used 
as a reference group in the multiple regression test because 
dual therapy with sulfonylurea and metformin is the most tra-
ditional combination. Statistical analyses were performed us-
ing SPSS version 20 (IBM Co., Armonk, NY, USA). Differenc-
es among groups with P<0.05 were considered statistically 
significant.
Initial 116 patients
Group II
(pioglitazone+metformin)
(n=37)
27 Study end  
without medication change
Group I
(sulfonylurea+metformin)
(n=33)
28 Study end  
without medication change
Group III
(sitagliptin+metformin)
(n=46)
33 Study end  
without medication change
Total 99 patients
17 Loss of follow-up
Medication change (n=3)
1 Very good response
1 Insufficient response
1 Hypoglycemia
Medication change (n=3)
1 Insufficient response
1 Gl trouble
1 Other cause
Medication change (n=5)
1 Very good response
3 Insufficient response
1 Gl trouble
Fig. 1. Flow of the study. A total of 116 patients were enrolled, and 99 subjects were analyzed in the study. Of these patients, 28 in 
the glimepiride/metformin group, 27 in the pioglitazone/metformin group, and 33 in the sitagliptin/metformin group complet-
ed the study without medication change. GI, gastrointestinal.
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RESULTS
Baseline characteristics of the study population
Of the 116 subjects who were enrolled in this study, 17 subjects 
failed to complete follow-up; 99 subjects were ultimately ana-
lyzed and were classified into three groups: group I (n=31, 
metformin and either gliclazide-MR [n=22 (71.0%), 60 (30 to 
60) mg] or glimepiride n=9 [29.0%], 4 [2.5 to 4] mg); group II 
(n=30, metformin and 15 mg pioglitazone), and group III 
(n=38, metformin and 100 mg sitagliptin) (Fig. 1). The base-
line characteristics of the subjects are described in Table 1. The 
mean age, body mass index (BMI), and median HbA1c level 
of the study population were 53.2 years, 26.7 kg/m2, and 9.1%, 
respectively. No significant difference in diabetes duration or 
Table 1. Baseline characteristics and daily metformin dose
Variable Total (n=99) Group I (n=31) Group II (n=30) Group III (n=38) P value
Demographic characteristics
Age, yr 53.2±12.1 54.8±11.6 55.2±9.7 50.2±13.7 0.160 
Male sex 58 (58.6) 16 (51.6) 18 (60.0) 24 (63.2) 0.615 
Diabetes duration, mo 1 (0, 12) 1 (0, 12) 5 (1, 19) 1 (0, 6) 0.377
Anthropometric characteristics
Height, cm 164.0±9.5 161.9±9.8 164.7±9.2 165.2±9.5 0.332
Weight, kg 72.1±13.0 69.9±15.4 71.4±11.8 74.5±11.6 0.332
BMI, kg/m2 26.±3.7 26.5±4.1 26.3±3.3 27.3±3.8 0.472 
Waist-to-hip ratio 0.93 (0.90, 0.96) 0.93 (0.90, 0.96) 0.92 (0.90, 0.99) 0.94 (0.90, 0.96) 0.945 
Blood pressure
Systolic, mm Hg 127.6±15.0 122.5±13.4 131.4±17.7 128.8±12.9 0.054
Diastolic, mm Hg 79.7±11.0 77.0±8.0 81.9±13.6 80.2±10.6 0.209 
Metabolic characteristics
FBS, mg/dL 173.0 (137.0, 211.0) 169.0 (141.0, 195.5) 170.5 (144.0, 211.0) 177.5 (135.0, 254.0) 0.605
PPG, mg/dL 251.0 (196.0, 315.0) 227.0 (199.0, 312.0) 240.5 (195.0, 317.0) 259.5 (198.0, 314.0) 0.704
HbA1c, % 9.1 (8.2, 10.6) 8.9 (8.2, 10.2) 8.8 (8.3, 11.2) 9.4 (7.9,11.1) 0.853
Total cholesterol, mg/dL 195.1±47.1 193.5±46.7 184.1±43.9 205.2±48.9 0.182
Triglyceride, mg/dL 133.0 (95.0, 232.0) 116.0 (90.5, 166.0) 132.5 (91.0, 168.0) 168.0 (107.0, 250.0) 0.116
HDL-C, mg/dL 43.0 (38.0, 49.0) 46.0 (41.5, 52.5) 40.0 (37, 49.0) 42 (39.0, 49.0) 0.187
LDL-C, mg/dL 109.1±45.9 113.9±48.8 99.3±36.5 113.0±49.8 0.371
HOMA-β 26.8 (17.5, 41.0) 24.3 (17.6, 48.8) 34.2 (19.7, 44.7) 25.6 (13.7, 38.7) 0.630
HOMA-IR 3.2 (2.5, 5.1) 3.0 (2.1, 3.9) 3.3 (2.8, 6.3) 3.6 (2.5, 5.6) 0.213
Miscellaneous
BUN, mg/dL 14.4±3.5 14.2±3.5 14.4±3.4 14.6±3.7 0.896
Creatinine, mg/dL 0.83±0.19 0.80±0.20 0.83±0.20 0.85±0.18 0.644
AST 22.0 (17.8, 31.0) 23.0 (18.0, 30.5) 22.5 (18.0, 32.0) 21.0 (17.0, 24.0) 0.683
ALT 25.5 (19.8, 37.5) 28.0 (20.5, 51.5) 25.5 (20.0, 39.0) 25.0 (20.0, 34.0) 0.694
Medication dose
Metformin, mg 1,000 (1,000, 1,700) 1,000 (1,000, 1,000) 1,000 (1,000, 1,700) 1,000 (1,000, 1,700) 0.006
Values are presented as mean±standard deviation, number (%), or median (low quartile, high quartile). Analysis of variance test was used for 
parametric analysis and Kruskal-Wallis test for nonparametric analysis.
BMI, body mass index; FBS, fasting blood glucose; PPG, postprandial glucose; HbA1c, hemoglobin A1c; HDL-C, high density lipoprotein cho-
lesterol; LDL-C, low density lipoprotein cholesterol; HOMA-β, homeostasis model assessment of β-cell function; HOMA-IR, homeostasis 
model assessment of insulin resistance; BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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baseline demographics, anthropometrics, or metabolic char-
acteristics was observed among the three groups. Daily met-
formin dose was smaller in group I than the other two groups 
(overall, P=0.006; group I vs. group II, P=0.001; group I vs. 
group III, P=0.012; group II vs. group III, P=0.064).
Tolerability and hypoglycemia assessment
The proportion of participants who completed the study with-
out change in dose or class of initial medications was 90.3% in 
the SU-treated group I (28/31), 90% in the pioglitazone-treat-
ed group II (27/30), and 86.8% in the sitagliptin-treated group 
III (33/38). There was no significant difference in study com-
pletion rate among the groups (P=0.925). In group I, one sub-
ject discontinued the study due to very good response and 
subsequent reduction of medications and another due to in-
sufficient response. In addition, one subject with symptoms of 
hypoglycemia was prescribed other drugs. In group II, one 
subject with an insufficient response, one subject with nausea, 
and one subject concerned with the risk of bladder cancer 
were switched to other drugs. In group III, one subject with a 
very good response, three subjects with an insufficient response, 
and one subject with nausea were switched to other drugs. No 
major hypoglycemic events occurred among the groups. In 
addition, one patient in group II reported transient diarrhea, 
but no other adverse events were reported.
Effectiveness assessment
Primary outcome
In the 88 patients who completed the study without change of 
initial medications, the median HbA1c level decreased from 
8.9% (8.2 to 10.3) to 6.5% (6.4 to 7.0; at 12-week) and to 6.4% 
(6.0 to 6.7; at 24-week) in the SU-treated group I (P<0.001 for 
each); from 9.0% (8.4 to 11.2) to 6.8% (6.5 to 7.3; at 12-week) 
and to 6.6% (6.1 to 6.9; at 24 weeks) in the pioglitazone-treated 
group II (P<0.001 for each); and from 9.3% (7.8 to 10.4) to 6.4% 
(6.3 to 7.0; at 12-week) and to 6.3% (6.0 to 6.7; at 24-week) (P< 
0.001 for each) in the sitagliptin-treated group III (Fig. 2). The 
median of individually assessed differences in HbA1c level 
from baseline to the 12- and 24-week end points were -2.2% 
(-3.7 to -1.8) and -2.5% (-4.0 to -1.9) in group I; -2.2% (-3.8 to 
-1.5) and -2.8% (-4.5 to -1.6) in group II; and -2.1% (-4.0 to 
-1.6) and -2.7% (-4.0 to -1.6) in group III, respectively. In ad-
dition, there was no significant difference in the change of 
HbA1c level of group II and III compared to group I after ad-
justing for baseline age, sex, BMI, and HbA1c at either the 12-
week (group II, P=0.101; group III, P=0.673) or 24-week end 
point (group II, P=0.066; group III, P=0.678) (Table 2, Fig. 2). 
However, after additional adjustment of metformin dose, group 
I showed superiority in HbA1c improvement to group II at the 
24-week end point (covariate-adjusted difference in change of 
HbA1c, 0.35%; P=0.046) (Table 2). Fasting plasma glucose 
level decreased from 166.5 (139.0 to 195.0) to 103.5 mg/dL 
(89.0 to 112.0) (P<0.001); 174.0 (145.0 to 223.0) to 111.0 mg/dL 
(101.5 to 120.0) (P<0.001); and 173.0 (135.0 to 204.0) to 105.0 
mg/dL (100.0 to 124.0) (P<0.001) in groups I, II, and III, re-
spectively. PPG level decreased from 226.5 (192.5 to 312.0) to 
157.0 mg/dL (133.5 to 196.5) (P<0.001); 238.0 (195.5 to 324.0) 
to 157.0 mg/dL (124.0 to 219.5) (P<0.001); and 251.0 (196.0 
to 306.0) to 148.0 mg/dL (115.0 to 172.0) (P<0.001) in groups 
I, II, and III, respectively. In addition, there was no significant 
difference in the change of FBG (group II, P=0.061; group III, 
P=0.070) or PPG (group II, P=0.914; group III, P=0.237) lev-
el among the groups after adjusting for baseline age, sex, BMI, 
and FBG or PPG. After additional adjustment of metformin 
dose, group I showed superiority in FBG improvement to 
group II and group III (covariate-adjusted difference in change 
of FBG: group 2, 15.9 mg/dL, P=0.008; group 3, 11.6 mg/dL, 
P=0.032), without significant difference in the change of PPG 
level.
Fig. 2. Change in hemoglobin A1c (HbA1c) from baseline to 
24 weeks. Solid lines indicate the median HbA1c level, and 
broken lines indicate the median of individually assessed dif-
ferences in HbA1c level from baseline. Multiple linear regres-
sion was used for statistical analysis, and group I was used as a 
reference group. The change of HbA1c was not statistically dif-
ferent among groups at 12 weeks (group II, P=0.101; group III, 
P=0.673) or 24 weeks (group II, P=0.066; group III, P=0.678) 
after adjustment for baseline age, sex, body mass index, and 
baseline HbA1c level.
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 The proportion of individuals who achieved HbA1c level 
≤7% at 24 weeks was 89.3%, 81.5%, and 84.8% in groups I, II, 
and III, respectively, with no statistically significant difference 
in the proportion among the groups (P=0.649) (Fig. 3A). To 
minimize selection bias, we performed an additional analysis. 
Subjects who achieved HbA1c level ≤7% at 24 weeks and those 
who reduced their medications because of a very good response 
during the study period were considered to have successfully 
controlled diabetes; however, other subjects, with the excep-
tion of those who did not continue with follow-up observation, 
were considered to have failed diabetes control. The proportion 
of individuals with successfully controlled diabetes was 83.9%, 
73.3%, and 76.3% in groups I, II, and III, respectively, with no 
statistically significant difference among the groups (P=0.593) 
(Fig. 3B).
Group I (n=28) Group II (n=27) Group III (n=33)
100
90
80
70
60
50
40
30
20
10
0
%
A
89.3
81.5
P=0.649
Proportions of individuals achieving HbA1c ≤7%
84.8
Group I (n=31) Group II (n=30) Group III (n=38)
100
90
80
70
60
50
40
30
20
10
0
%
B
83.9
73.3
P=0.593
Proportions of overall successful diabetes control
76.3
Fig. 3. (A) The proportions of individuals who achieved hemo-
globin A1c (HbA1c) level ≤7% at 24 weeks, and (B) the pro-
portions of individuals with overall successful diabetes control 
according to medication. (A) Dark gray bar indicates the pro-
portion of individuals who achieved an HbA1c level ≤7% 
among those who did not change medications by the end of the 
study. Fisher exact test was used to compare the three groups, 
and there was no significant difference (P=0.649). (B) Light 
gray bar indicates the proportion of individuals, among the to-
tal number of subjects who initially enrolled in the study, except 
for those who did not continue with follow-up observation, 
who achieved an HbA1c level ≤7% at 24 weeks or reduced 
medication during the study period because of a very good re-
sponse. The Fisher exact test was used to compare the three 
groups, and there was no significant difference (P=0.593).
Table 2. Covariate-adjusted differences in change of hemoglo-
bin A1c
Unstandardized  
coefficients, 
%HbA1c
P value
Variants (model 1)
Group II (group I is a reference) 0.298 0.066
Group III (group I is a reference) 0.065 0.678
Age, yr 0.001 0.890
Female (male is a reference) -0.074 0.567
BMI, kg/m2 -0.039 0.027
Baseline HbA1c, % -1.063 <0.001
Variants (model 2)
Group II (group I is a reference) 0.220 0.163
Group III (group I is a reference) -0.010 0.950
Age, yr -0.001 0.863
Female (male is a reference) -0.064 0.610
BMI, kg/m2 -0.051 0.008
Baseline HbA1c, % -1.125 <0.001
HOMA-β -0.005 0.012
HOMA-IR 0.066 0.010
Variants (model 3)
Group II (group I is a reference) 0.353 0.046
Group III (group I is a reference) 0.089 0.577
Age, yr -0.001 0.903
Female (male is a reference) -0.076 0.560
BMI, kg/m2 -0.037 0.039
Baseline HbA1c, % -1.047 <0.001
Daily metformin dose, g -0.191 0.423
In model 1, which adjusts for baseline age, sex, BMI, and HbA1c, there 
was no significant difference between groups in change of HbA1c 
(group II, P=0.066; group III, P=0.678). Additional adjustment of 
HOMA-β and HOMA-IR did not alter the statistical significance. 
However, after additional adjustment of daily metformin dose, group 
II showed a statistically smaller reduction in HbA1c than group I 
(covariate-adjusted difference in change of HbA1c, 0.35%; P=0.046). 
HbA1c, hemoglobin A1c; BMI, body mass index; HOMA-β, homeo-
stasis model assessment of β-cell function; HOMA-IR, homeostasis 
model assessment of insulin resistance.
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Secondary and other outcomes
The subjects were also classified into three categories accord-
ing to HbA1c level: category I (n=43; 7.5%≤HbA1c<9.0%), 
category II (n=23; 9.0%≤HbA1c<11.0), and category III 
(n=22; 11.0%≤HbA1c) (Table 3). In addition to different 
HbA1c level (8.1% vs. 9.9% vs. 11.6%; P<0.001), HOMA-β 
(34.2 vs. 25.6 vs. 19.8; P=0.008), and HOMA-IR (2.8 vs. 3.6 vs. 
3.5; P=0.005) were also significantly different among the cate-
gories. The daily dose of metformin was higher in category III 
than in the other two categories (1,000 mg vs. 1,000 mg vs. 
1,700 mg; P<0.001). Despite the difference in baseline HbA1c 
level and HOMA, no statistically significant difference was ob-
served among the categories after 24 weeks (6.4% [6.1 to 6.8] 
vs. 6.6% [6.2 to 6.7] vs. 6.0% [5.7 to 6.6)], P=0.051) (Fig. 4). 
The proportion of individuals who achieved HbA1c ≤7% at 
24 weeks was 83.7%, 87.0%, and 86.4% in categories I, II, and 
III, respectively, with no statistically significant difference 
among the categories (P=1.000) (Fig. 5A). The proportion of 
individuals with overall successful diabetes control, as defined 
above, was 75.0%, 81.5%, 79.2% and similar among categories 
I, II, and III, respectively (P=0.819) (Fig. 5B).
DISCUSSION
It is well known that significant prevention and reduction of mi-
crovascular and macrovascular complications can be achieved 
with early intensive glycemic control in subjects with newly 
detected T2D [1,3]. However, to date, scientific studies investi-
gating an optimal combination regimen for metformin-based 
OHA therapy and its glucose-lowering efficacy have been es-
pecially lacking in Korean subjects with T2D. On the basis of 
previous research, this study focused on the practical implica-
tions of a combination regimen for metformin-based OHA 
therapy in newly diagnosed or drug-naïve Korean T2D pa-
tients. Therefore, we attempted to investigate: 1) the tolerabili-
ty and efficacy of metformin-based dual combination therapy 
with OHAs by assessing the reduction of HbA1c level as well 
as the proportion of subjects reaching a target HbA1c level 
≤7%; and 2) the appropriateness of current guidelines estab-
lished by the NHIC of Korea, which mandates the number of 
Table 3. Baseline characteristics and daily metformin dose of three categories according to baseline hemoglobin A1c level
Variable Total (n=88) Category I (n=43) Category II (n=23) Category III (n=22) P value
Metformin dose, mg 1,000 (1,000, 1,700) 1,000 (1,000, 1,000) 1,000 (1,000, 1,000) 1,700 (1,000, 1,700) <0.001a,b
Age, yr 53.1±11.3 55.1±9.7 52.0±13.9 50.6±11.2 0.283 
Males 52 (59.1) 23 (53.5) 15 (65.2) 14 (63.6) 0.613 
BMI, kg/m2 26.6±3.7 26.4±3.2 27.6±4.4 26.1±3.8 0.353 
HbA1c, % 9.1 (8.1, 10.8) 8.1 (7.7, 8.5) 9.9 (9.5, 10.1) 11.6 (11.3, 12.6) <0.001a,b,c
HOMA-β 25.7 (18.1, 41.1) 34.2 (22.2, 62.5) 25.6 (19.8, 35.7) 19.8 (9.7, 29.7) 0.008a
HOMA-IR 3.2 (2.5, 4.7) 2.8 (1.8, 3.4) 3.6 (3.2, 4.7) 3.5 (2.5, 7) 0.005c
Values are presented as median (low quartile, high quartile), mean±standard deviation, or number (%). Analysis of variance test was used for 
parametric analysis and Kruskal-Wallis test for nonparametric analysis.
BMI, body mass index; HbA1c, hemoglobin A1c; HOMA-β, homeostasis model assessment of β-cell function; HOMA-IR, homeostasis model 
assessment of insulin resistance.
aStatistical significance (P<0.017) in post hoc analysis (Mann-Whitney test with Bonferroni correction) was indicated by category I vs. III, bCat-
egory II vs. III, cCategory I vs. II.
Fig. 4. Change in hemoglobin A1c (HbA1c) according to base-
line HbA1c level. Dark gray bar indicates the level at baseline 
and light gray bar at 24 weeks. Bars represent medians (low 
quartile, high quartile). Despite different initial HbA1c levels 
(8.2% vs. 9.9% vs. 11.9%; P<0.001), HbA1c level in each cate-
gory after 24 weeks of treatment demonstrated no statistical 
difference by Kruskal-Wallis test (6.4% vs. 6.6% vs. 6.0%; P= 
0.051).
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OHAs prescribed by analyzing the proportion of subjects 
reaching a target HbA1c level ≤7% according to initial HbA1c.
 In this study, 99 Korean T2D subjects who were newly diag-
nosed with the disease or who were drug-naïve underwent 
dual therapy with a combination of metformin and OHA (SU 
[either gliclazide-MR or glimepiride], 15 mg pioglitazone, or 
100 mg sitagliptin) over a 24-week study period. By the end of 
the study, the percentage of subject with initial HbA1c level 
≥7.5% decreased by 2.5% to 2.7%. In previous studies, most 
OHAs decreased HbA1c level by about 1% when used as a 
monotherapy, and by about 2% when used as a combination 
therapy [8,9]. The differences between our results and those of 
previous studies might be due to the higher baseline HbA1c 
levels, drug-naïve characteristics, and lower insulin resistance 
of our subjects. Our study did not exclude subjects with very 
high HbA1c level, unlike many previous studies which set an 
upper limit of initial HbA1c [10-12]. Moreover, the baseline 
HbA1c (9.1%) of our study was higher than those of most pre-
vious studies (7.6% to 8.8%) [10-15]. Because initial HbA1c 
level did not alter the endpoint HbA1c level in our study, this 
higher baseline HbA1c seems to have mostly affected the de-
gree of HbA1c reduction. Contrary to many studies evaluating 
patients taking OHA prior to the study, which reported higher 
HbA1c (6.9% to 7.2%) at endpoint than our study [13,14], sev-
eral studies evaluating drug-naïve diabetes patients observed 
final HbA1c levels of about 6.5% after using a combination of 
two drugs, which is similar to our results [10-12]. The HOMA-
IR of our study (3.2) was lower than those of previous studies 
(3.6 to 7.0) [12-14,16]. Even though HOMA-IR has limited 
value when compared across different populations [17], this 
finding may suggest that our subjects had better insulin sensi-
tivity than subjects in previous studies.
 In the aspects of tolerability and glycemic effectiveness, the 
three dual therapies using a combination of metformin and ei-
ther sulfonylurea, pioglitazone, or sitagliptin led to similar 
proportions of subjects adhering to the initial regimen, similar 
degrees of HbA1c improvement, and similar proportions of 
subjects reaching the target HbA1c level. However, after ad-
justment of daily metformin dose, which was determined ac-
cording to physician judgment in usual practice, sulfonylurea 
reduced HbA1c by a greater magnitude than did pioglitazone. 
This finding suggests that pioglitazone and metformin combi-
nation could partially overcome the lower intrinsic potency of 
pioglitazone by using a higher dose of metformin in real prac-
tice.
 Interestingly, baseline HbA1c level did not affect the endpoint 
HbA1c level in this study. Moreover, the proportion of indi-
viduals who reached a target HbA1c level ≤7.0% was similar 
across the groups, although their baseline HbA1c levels were 
significantly different. It is well known that patients with high-
er baseline HbA1c level have greater reduction of HbA1c irre-
spective of drug class [18,19]. Because each drug results in a 
Category I (n=43) Category II (n=23) Category III (n=22)
100
90
80
70
60
50
40
30
20
10
0
%
A
83.7 87.0
P=1.000
Proportions of individuals achieving HbA1c ≤7%
86.4
Category I (n=48) Category II (n=27) Category III (n=24)
100
90
80
70
60
50
40
30
20
10
0
%
B
75.0
81.5
P=0.819
Proportions of overall successful diabetes control
79.2
Fig. 5. (A) The proportions of individuals who achieved an hemoglobin A1c (HbA1c) level ≤7% at 24 weeks, and (B) the propor-
tions of individuals with overall successful diabetes control according to baseline HbA1c level. Category I, 7.5%≤HbA1c<9.0; 
category II, 9.0%≤HbA1c<11.0; category III, 11.0%≤ HbA1c. (A) Dark gray bar indicates the proportion of individuals who 
achieved an HbA1c level ≤7% among those who did not change medications by the end of the study. Fisher exact test was used 
to compare the three groups, and there was no significant difference (P=1.000). (B) Light gray bar indicates the proportion of in-
dividuals, among the total number subjects who initially enrolled in the study, except for those who did not continue with follow-
up observation, who achieved an HbA1c level ≤7% at 24 weeks or reduced medication during the study period because of a very 
good response. Fisher exact test was used to compare the three groups, and there was no significant difference (P=0.819).
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greater reduction of HbA1c according to higher baseline HbA1c, 
when two drugs are used simultaneously, the increased reduc-
tion of HbA1c according to higher baseline HbA1c might 
show a greater magnitude due to the additive effect. This ten-
dency was also shown in previous studies, even though statis-
tical analysis was not performed [10,19]. Another possible ex-
planation is preserved insulin sensitivity of the study patients. 
HOMA-IR of subjects with the highest initial HbA1c level was 
3.5 in this study, which was relatively lower than reported in 
other studies (3.6 to 7.0) which have assessed the efficacy of 
dual regimens [12-15]. In our study, a one unit increase of 
HOMA-IR resulted in a 0.066%, increase of HbA1c at end-
point. The other explanation is the higher metformin dose for 
patients with higher initial HbA1c level. These results indicate 
that, even at a very high baseline HbA1c level, therapy with a 
combination of two drugs may still be effective in drug-naïve 
subjects whose insulin sensitivity remains preserved. This 
finding supports the current guidelines for OHA selection, 
which do not recommend initial therapy using a combination 
of three OHAs [4-6].
 This study has several limitations. The patients were not 
randomized, and the criteria for changing medications were 
not uniform because all treatment decisions were determined 
by diabetologists specifically for each patient. However, the 
baseline characteristics of the three groups did not show statis-
tically significant differences. Furthermore, supplemental anal-
ysis of all subjects, except for those who did not continue with 
follow-up observation, showed similar statistical results to the 
analysis of subjects who did not change their medications 
throughout the study. In addition, the number of participants 
was small, and the rate of follow-up loss was 14.7% at the end 
of the study. Therefore, the reliability of our trial was lower 
than originally expected at the time the study was first de-
signed.
 In conclusion, metformin-based dual combination thera-
pies with OHAs including sulfonylurea, pioglitazone, or sita-
gliptin showed similar glycemic effectiveness in drug-naïve 
Korean subjects with newly diagnosed T2D. Combination 
therapy using these OHA drugs was similarly effective in pa-
tients with a wide range of initial HbA1c level. Based on these 
results, we suggest the appropriateness of the current guide-
lines established by the NHIC of Korea, which do not allow 
initial three drug combinations and recommend metformin-
based dual combination therapy with OHAs including sulfo-
nylurea, pioglitazone, or DPP4-inhibitor in subjects with ini-
tial HbA1c level ≥7.5%. This study is the first to compare the 
glycemic effectiveness of dual combination agents commonly 
used as primary medications in Korean T2D patients. An ad-
ditional randomized study with a larger number of subjects is 
warranted to obtain more detailed information including glu-
cose variability.
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